A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models

PloS One
Stacie LambertRoderick S Tang

Abstract

Illness associated with Respiratory Syncytial Virus (RSV) remains an unmet medical need in both full-term infants and older adults. The fusion glycoprotein (F) of RSV, which plays a key role in RSV infection and is a target of neutralizing antibodies, is an attractive vaccine target for inducing RSV-specific immunity. BALB/c mice and cotton rats, two well-characterized rodent models of RSV infection, were used to evaluate the immunogenicity of intramuscularly administered RSV vaccine candidates consisting of purified soluble F (sF) protein formulated with TLR4 agonist glucopyranosyl lipid A (GLA), stable emulsion (SE), GLA-SE, or alum adjuvants. Protection from RSV challenge, serum RSV neutralizing responses, and anti-F IgG responses were induced by all of the tested adjuvanted RSV sF vaccine formulations. However, only RSV sF + GLA-SE induced robust F-specific TH1-biased humoral and cellular responses. In mice, these F-specific cellular responses include both CD4 and CD8 T cells, with F-specific polyfunctional CD8 T cells that traffic to the mouse lung following RSV challenge. This RSV sF + GLA-SE vaccine formulation can also induce robust RSV neutralizing titers and prime IFNγ-producing T cell responses in Sprague Dawley rats...Continue Reading

References

Apr 1, 1991·The Journal of Infectious Diseases·C B HallK C Schnabel
Feb 17, 1998·European Journal of Immunology·T HussellP J Openshaw
Oct 22, 2002·Expert Opinion on Biological Therapy·Leonard R Krilov
Aug 20, 2003·Nature Medicine·Erika HammarlundMark K Slifka
Jan 15, 2004·The Journal of Infectious Diseases·Edward E WalshAnn R Falsey
Sep 29, 2004·Antiviral Research·F Eun-Hyung LeeJohn J Treanor
Dec 15, 2004·Microbes and Infection·Chandrashekhar Pasare, Ruslan Medzhitov
Feb 1, 2005·Journal of Virology·Stephen P MatthewsPeter J M Openshaw
Jun 4, 2005·Advances in Experimental Medicine and Biology·Chandrashekhar Pasare, Ruslan Medzhitov
Jan 4, 2007·Kidney International·X-M LiuY Guo
Jan 5, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Juan J LasarteClaude Leclerc
Sep 12, 2007·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·T PolteG Hansen
Nov 6, 2007·Advances in Immunology·Falk Nimmerjahn, Jeffrey V Ravetch
Dec 8, 2007·Nature Reviews. Immunology·Falk Nimmerjahn, Jeffrey V Ravetch
Mar 8, 2008·Nature Reviews. Immunology·Robert A SederMario Roederer
May 1, 2008·Expert Review of Vaccines·Rajesh Kumar, Edith A Burns
Oct 7, 2008·Archivum Immunologiae Et Therapiae Experimentalis·Sheela RamanathanSubburaj Ilangumaran
Oct 11, 2008·Expert Review of Vaccines·Matthew R Olson, Steven M Varga
Jun 9, 2009·Seminars in Immunology·Santhakumar Manicassamy, Bali Pulendran
Sep 15, 2009·Colloids and Surfaces. B, Biointerfaces·Ryan C AndersonThomas S Vedvick
Apr 27, 2011·Proceedings of the National Academy of Sciences of the United States of America·Megan K L MacLeodPhilippa Marrack
May 17, 2011·Drug Discovery Today·Marie-Luce De TemmermanStefaan C De Smedt
May 19, 2011·Proceedings of the National Academy of Sciences of the United States of America·Kurt A SwansonAndrea Carfi
Jun 28, 2011·The American Journal of Pathology·Sumanta MukherjeeNicholas W Lukacs

❮ Previous
Next ❯

Citations

Oct 28, 2015·Expert Review of Vaccines·Noushin JaberolansarMariusz Skwarczynski
Dec 8, 2015·Expert Review of Vaccines·Patricia A JorqueraRalph A Tripp
Oct 13, 2015·Expert Opinion on Investigational Drugs·Claudia A RiveraAlexis M Kalergis
Aug 8, 2015·Vaccine·Fernando P Polack
Jun 1, 2015·Current Opinion in Immunology·Karen BohmwaldAlexis M Kalergis
Jul 9, 2016·Current Opinion in Immunology·Steven G ReedMark T Orr
May 21, 2017·Expert Review of Vaccines·Tonya VillafanaMark T Esser
Sep 16, 2016·AAPS PharmSciTech·Jenny SunGautam Sanyal
Aug 12, 2017·International Journal of Molecular Sciences·Nicolás M S GálvezAlexis M Kalergis
May 18, 2018·Human Vaccines & Immunotherapeutics·Jorge C G BlancoStefanie N Vogel
May 18, 2018·Antiviral Chemistry & Chemotherapy·M S BoukhvalovaJcg Blanco
Oct 13, 2017·Clinical and Vaccine Immunology : CVI·Cindy ShambaughMark T Esser
Dec 18, 2015·Clinical and Vaccine Immunology : CVI·Patricio L AcostaFernando P Polack
Mar 12, 2019·Human Vaccines & Immunotherapeutics·Adriana WeinbergMyron J Levin
Aug 19, 2020·Expert Opinion on Pharmacotherapy·Alexis M KalergisSusan M Bueno
Dec 21, 2018·Frontiers in Microbiology·Maria K SmattiHadi M Yassine
May 21, 2019·F1000Research·Sofia Jares Baglivo, Fernando P Polack
May 10, 2019·Cancer Immunology, Immunotherapy : CII·Amit MahipalKunle Odunsi
Oct 6, 2020·Frontiers in Immunology·Maria TrovatoPiergiuseppe De Berardinis
Oct 21, 2016·Bioconjugate Chemistry·Joseph R FrancicaRobert A Seder

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
blood draws

Software Mentioned

ViCell

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Babesiosis

Babesiosis is caused by parasites of the genus babesia, which are transmitted in nature by the bite of an infected tick. Discover the latest research on babesiosis here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.